ASCO2025

Izzah NawazMyeloma | June 11, 2025
Elranatamab shows durable responses and manageable safety in heavily pretreated US patients with myeloma.
Read More
Izzah NawazMeeting News | June 11, 2025
Blood clot risk tools may fall short for myeloma patients—study shows aspirin alone might not be enough.
Izzah NawazMeeting News | June 11, 2025
Belantamab may return for RRMM after DREAMM trials show benefit, despite ongoing concerns about eye toxicity.
Advertisement
Andrew MorenoMeeting News | June 11, 2025
The three-arm study enrolled patients with disease refractory to prior carfilzomib, daratumumab, or pomalidomide therapy.
Melissa BadamoMyeloma | June 10, 2025
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
Blood Cancers Today Staff WritersMeeting News | June 9, 2025
AI is revolutionizing oncology with faster analysis, better predictions, and more personalized cancer care.
Ruben A. Mesa, MDMyeloproliferative Neoplasms | June 6, 2025
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Andrew MorenoMeeting News | June 5, 2025
Peripheral blood samples were analyzed within a phase 2 trial of this bispecific antibody as 1L treatment for FL and MZL.
Robert ZadottiMantle Cell Lymphoma | June 5, 2025
Ibrutinib plus venetoclax shows strong CR rates and durable remissions in older and younger MCL patients with TP53 mutations.
Robert ZadottiChronic Lymphocytic Leukemia | June 4, 2025
Zanubrutinib and venetoclax show deep and lasting responses in frontline CLL and SLL including those with del 17p or TP53.
Andrew MorenoMeeting News | June 4, 2025
A fixed duration regimen of the combination was compared with a regimen guided by measurable residual disease.
Melissa BadamoFollicular Lymphoma | June 3, 2025
Of 128 efficacy-evaluable patients, the ORR was 80.5% and the CR rate was 74.2% at a median follow-up of 28.3 months.
Melissa BadamoMyelodysplastic Syndromes | June 10, 2025
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
David J. Andorsky, MDChronic Myeloid Leukemia | June 3, 2025
Dr. Andorsky discusses CML dose escalation, treatment discontinuation, and unmet needs in leukemia care.
Melissa BadamoMyelodysplastic Syndromes | June 3, 2025
Frontline luspatercept demonstrates superior efficacy compared with ESAs in patients with lower-risk MDS.
Catherine Lai, MD, MPHAcute Lymphoblastic Leukemia | June 3, 2025
100% MRD-negative CR in Ph+ ALL? Dr. Catherine Lai recaps standout abstracts from an ASCO rapid oral session.
Melissa BadamoMyeloma | June 11, 2025
The median progression-free survival was 33.2 months in the BVd arm, compared with 11.1 months in the DVd arm.
Melissa BadamoMyelodysplastic Syndromes | June 2, 2025
Naval Daver, MD, presented on the efficacy and safety of bexmarilimab plus standard-of-care azacitidine for MDS at ASCO 2025.
Constantine Tam, MD, MBBSChronic Lymphocytic Leukemia | June 3, 2025
Dr. Tam reviews 5-year data from SEQUOIA showing strong efficacy of zanubrutinib in older CLL patients with 17p deletion.
Andrew MorenoMeeting News | June 11, 2025
Belantamab mafodotin plus pomalidomide-dexamethasone showed greater efficacy to pomalidomide-bortezomib-dexamethasone.
Advertisement
Advertisement